2. Academic Validation
  3. CaMKII inhibition protects against hyperthyroid arrhythmias and adverse myocardial remodeling

CaMKII inhibition protects against hyperthyroid arrhythmias and adverse myocardial remodeling

  • Biochem Biophys Res Commun. 2022 Jul 30;615:136-142. doi: 10.1016/j.bbrc.2022.04.082.
Daan Nie 1,  Chaorui Xia 2,  Zhiyu Wang 1,  Peiwu Ding 1,  Yidi Meng 1,  Jie Liu 1,  Ting Li 1,  Ting Gan 1,  Baijun Xuan 1,  Yun Huang 3,  Jiaming Zhang 1,  Guanhua Su 1,  Jingdong Li 4
Affiliations

Affiliations

  • 1 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • 2 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China; Department of Cardiology, Jingzhou First People's Hospital, The First Affiliated Hospital of Yangtze University, Jingzhou, 434000, China.
  • 3 Department of Gerontology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • 4 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Electronic address: jingdong-li@mail.hust.edu.cn.
PMID: 35617800 DOI: 10.1016/j.bbrc.2022.04.082
Abstract

Hyperthyroidism can potentiate arrhythmias and cardiac hypertrophy, whereas CA2+/calmodulin-dependent kinase II (CaMKII) promotes maladaptive myocardial remodeling. However, it remains unclear whether CaMKII contributes to the progression of hyperthyroid heart disease (HHD). This study demonstrated that CaMKII inhibition can relieve adverse myocardial remodeling and reduce sinus tachycardia, isoproterenol-induced atrial fibrillation, and ventricular arrhythmias in hyperthyroid mice with preserved heart function. Hyperthyroid cardiac hypertrophy was promoted by CaMKII upregulation-induced HDAC4/MEF2a activation. Briefly, CaMKII inhibition benefits HHD management greatly in mice by preventing arrhythmias and maladaptive remodeling.

Keywords

Adverse myocardial remodeling; CaMKII; HDAC4; Hyperthyroid heart disease (HHD); MEF2a; Sinus tachycardia.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15465
    99.19%, CaMK II Inhibitor‎